{"title":"Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.","authors":"K Machka, I Braveny","doi":"10.1007/BF02013116","DOIUrl":null,"url":null,"abstract":"<p><p>The in vitro activity of RO 23-6240 was compared with that of norfloxacin, ofloxacin and ciprofloxacin as well as four other antimicrobial agents against 345 recent clinical isolates. The MICs of RO 23-6240 against Enterobacteriaceae and Acinetobacter anitratum was less than or equal to 0.5 mg/l. At the same concentration of the compound 90% of staphylococci were inhibited. Against Enterococcus faecalis and Pseudomonas aeruginosa RO 23-6240 proved less active, having MIC90 values of 4.0 mg/l and 8.0 mg/l, respectively. Enterobacteriaceae and staphylococci strains that were resistant to piperacillin, cefotaxime or tobramycin were susceptible to the compound. In general the activity of RO 23-6240 was comparable to those of norfloxacin and ofloxacin, but less than that of ciprofloxacin.</p>","PeriodicalId":11958,"journal":{"name":"European Journal of Clinical Microbiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02013116","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02013116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
The in vitro activity of RO 23-6240 was compared with that of norfloxacin, ofloxacin and ciprofloxacin as well as four other antimicrobial agents against 345 recent clinical isolates. The MICs of RO 23-6240 against Enterobacteriaceae and Acinetobacter anitratum was less than or equal to 0.5 mg/l. At the same concentration of the compound 90% of staphylococci were inhibited. Against Enterococcus faecalis and Pseudomonas aeruginosa RO 23-6240 proved less active, having MIC90 values of 4.0 mg/l and 8.0 mg/l, respectively. Enterobacteriaceae and staphylococci strains that were resistant to piperacillin, cefotaxime or tobramycin were susceptible to the compound. In general the activity of RO 23-6240 was comparable to those of norfloxacin and ofloxacin, but less than that of ciprofloxacin.